In vitro sensitivity to 5-FU and gemcitabine in pancreatic cancer

被引：0
|
作者：
Franko, J.
Bilimoria, M. M.
Chalikonda, S.
Iannitti, D. A.
机构：
[1] Mercy Med Ctr, Des Moines, IA USA
[2] Adv Surg Associates, Arlington Hts, IL USA
[3] Cleveland Clin, Cleveland, OH 44106 USA
[4] Carolinas HealthCare Syst, Charlotte, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 04期
关键词：
D O I：
10.1200/jco.2011.29.4_suppl.312
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
312
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Gemcitabine/5-FU/leucovorin for the treatment of pancreatic cancer
    Malayeri, R.
    Boland, M. Ghassem
    Maadi, A. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Comparison of 5-FU and leucovorin to gemcitabine in the treatment of pancreatic cancer
    Klein, B
    Sadikov, E
    Mishaeli, M
    Levin, I
    Figer, A
    ONCOLOGY REPORTS, 2000, 7 (04) : 875 - 877
  • [3] Chemoradiotherapy with Gemcitabine and Continuous 5-FU in Patients with Primary Inoperable Pancreatic Cancer
    Wilkowski, Ralf
    Thoma, Martin
    Bruns, Christiane
    Wagner, Andreas
    Heinemann, Volker
    JOURNAL OF THE PANCREAS, 2006, 7 (04): : 349 - 360
  • [4] Gemcitabine and protracted 5-FU for advanced pancreatic cancer.: A phase II study
    Kurtz, JE
    Kohser, F
    Négrier, S
    Trillet-Lenoir, V
    Walter, S
    Limacher, JM
    Untereiner, M
    Kayitalire, L
    Jaeck, D
    Dufour, P
    HEPATO-GASTROENTEROLOGY, 2000, 47 (35) : 1450 - 1453
  • [5] The mechanism by which pancreatic cancer cells acquire drug resistance against 5-FU and gemcitabine
    石欣
    China Medical Abstracts, 2003, (02) : 76 - 76
  • [6] JCO Flashback: Comparing the Performance of Gemcitabine With 5-FU in Treating Advanced Pancreatic Cancer (1997)
    不详
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (36) : 5481 - 5481
  • [7] The therapeutic effects of 5-FU and luteolin in pancreatic cancer
    Kato, Hiroyuki
    Naiki, Aya
    Inaguma, Shingo
    Komura, Masayuki
    Takahashi, Satoru
    CANCER SCIENCE, 2024, 115 : 1922 - 1922
  • [8] 5-FU/Gemcitabine resistance is associated with epitherial-mesenchymal transition in pancreatic cancer cell lines
    Morimoto, Masaki
    Honjo, Soichiro
    Amisaki, Masataka
    Fujiwara, Yoshiyuki
    CANCER SCIENCE, 2018, 109 : 1403 - 1403
  • [9] A PHASE III STUDY COMPARING LAROTAXEL TO 5-FU (CONTINUOUS INTRAVENOUS 5-FU OR CAPECITABINE) IN PATIENTS WITH ADVANCED PANCREATIC CANCER (APC) PREVIOUSLY TREATED WITH A GEMCITABINE CONTAINING REGIMEN
    Van Cutsem, E.
    Macarulla, T.
    Van Laethem, J.
    Couture, F.
    Peeters, M.
    Hoff, Gehn M.
    Roman, L.
    Lequesne, L.
    Charpentier, E.
    Conroy, T.
    ANNALS OF ONCOLOGY, 2010, 21 : 12 - 13
  • [10] Gemcitabine(GEM) plus B-fluorouracil (5-FU) by modulated by leucovorin (LV) for advanced pancreatic cancer)
    Polyzos, A
    Tsavaris, N
    Kosmas, C
    Arnaoutis, T
    Apostolopoulos, P
    Vafiadis, I
    Tsatali, K
    Toskas, A
    Nikou, G
    ANNALS OF ONCOLOGY, 1998, 9 : 55 - 55
12345